Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

NCT07370909 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG: LW402
DRUG: Placebo

Sponsor

Shanghai Longwood Biopharmaceuticals Co., Ltd.

Collaborators

[object Object]